Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Extended
フラクショナル・フロー・リザーブ対血管造影による多血管評価(FAME)3 拡張:フラクショナル・フロー・リザーブガイド下経皮的冠動脈インターベンションと冠動脈バイパス移植術の比較(多枝冠動脈疾患患者対象)
Coronary artery disease, or narrowing of the blood vessels that provide blood to the heart, is the most common cause of death in the United States and can be treated with either coronary bypass surgery or coronary stent placement. This study will evaluate outcomes, including death and quality of life, at 10 years in 1,500 patients with coronary disease who have already been randomized to either bypass surgery or stenting.
調査の概要
詳細な説明
Coronary artery disease (CAD) remains the major cause of morbidity and mortality in adults in the United States. In patients with 3-vessel CAD not involving the left main coronary artery, percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) can improve outcomes. Older studies have shown that the more invasive option, CABG, significantly reduces mortality during long-term follow-up compared with PCI. However, these studies did not use contemporary methods to perform PCI, such as measuring an index called fractional flow reserve (FFR) with a coronary pressure wire or using current- generation drug-eluting stents (DES), both of which significantly improve outcomes after PCI. The Fractional flow reserve versus Angiography for Multivessel Evaluation (FAME) 3 trial randomized 1,500 patients to FFR-guided PCI with current generation DES or to CABG and found that at 5 years there was no significant difference in the composite of death, myocardial infarction (MI) or stroke between the two strategies. There was a reduction in MI in the CABG group. Longer-term follow-up is critical to determine if contemporary PCI results in similar survival as CABG. The primary aim of this project is to determine if 10-year mortality is different after FFR-guided PCI compared with CABG. Investigators will perform 10-year follow-up in the 1,500 patients randomized in the FAME 3 trial to determine if FFR-guided PCI is non-inferior to CABG with respect to mortality. Secondary aims include assessing quality of life and angina relief at 10 years in the two groups. Additionally, investigators will compare individual rates of secondary clinical outcomes including MI, stroke, and repeat revascularization at 10-year follow-up after PCI or CABG.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
California
-
Stanford、California、アメリカ、94305
- Stanford University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
This study will evaluate outcomes, including death and quality of life, at 10 years in 1,500 patients with coronary disease who have already been randomized to either bypass surgery or stenting.
説明
Inclusion Criteria:
-
Age ≥ 21 years with angina and/or evidence of myocardial ischemia
-
Three vessel CAD, defined as ≥ 50% diameter stenosis by visual estimation in each of the three major epicardial vessels or major side branches, but not involving left main coronary artery, and amenable to revascularization by both PCI and CABG as determined by the Heart Team. Patients with a non-dominant right coronary artery may be included if only the left anterior descending artery (LAD) and left circumflex have
≥50% stenosis
-
Willing and able to provide informed, written consent
Exclusion Criteria:
- Requirement for other cardiac or non-cardiac surgical procedure (e.g., valve replacement, carotid revascularization), however a maze procedure or pulmonary vein isolation is allowed
- Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support
- Recent STEMI (<5 days prior to randomization)
- Ongoing Non STEMI with biomarkers (cardiac troponin) still rising
- Known left ventricular ejection fraction <30%
- Life expectancy < 2 years
- Requiring renal replacement therapy
- Undergoing evaluation for organ transplantation
- Participation or planned participation in another clinical trial, except for observational registries
- Pregnancy
- Inability to take dual antiplatelet therapy or anticoagulation and single antiplatelet therapy for at least six months
- Previous CABG
- Left main disease requiring revascularization
- Extremely calcified or tortuous vessels precluding FFR measurement
- Any target lesion with in-stent drug-eluting stent restenosis
- More than one major epicardial vessel which is chronically occluded
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
FFR-guided PCI group
These patients have undergone fractional flow reserve-guided percutaneous coronary intervention |
Coronary stenting compared with coronary bypass surgery |
|
CABG group
These patients underwent coronary artery bypass grafting surgery |
Coronary artery bypass surgery |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Survival
時間枠:10-year follow-up
|
The primary outcome is mortality or overall survival |
10-year follow-up
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Quality of life
時間枠:10-year follow-up
|
Secondary aims include assessing quality of life at 10 years in the two groups utilizing the EQ-5D quality of life questionnaire. |
10-year follow-up
|
|
Angina Relief
時間枠:10 year follow-up
|
Secondary aims include assessing angina status at 10 years in the two groups utilizing the Seattle Angina Questionnaire. |
10 year follow-up
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Major adverse cardiac events
時間枠:10 year follow-up
|
Additionally, we will compare individual rates of secondary clinical outcomes including myocardial infarction (MI), stroke, and repeat revascularization and combinations of the above, including death and MI, and death, MI, or stroke at 10-year follow-up after PCI or CABG. |
10 year follow-up
|
協力者と研究者
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 83374
- 1R01HL179196-01 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。